File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Conference Paper: Evolution of neoadjuvant chemotherapy in locally advanced HER2-positive breast cancer over 10 years in Hong Kong

TitleEvolution of neoadjuvant chemotherapy in locally advanced HER2-positive breast cancer over 10 years in Hong Kong
Authors
Issue Date2015
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
The 2015 Congress of the European Society for Medical Oncology Asia (ESMO Asia 2015), Singapore, 18-22 December 2015. In Annals of Oncology, 2015, v. 26 suppl. 9, p. ix22, abstract no. 71P How to Cite?
AbstractAIM/BACKGROUND: Over the last 10 years we witnessed major changes in treatment for locally advanced HER2-positive breast cancer. The emergence of multiple anti-HER2 therapies and recognition of pathological complete response (pCR) as the surrogate marker for survival are the major landmarks. The clinical benefit of this approach and effects on patient behaviour in Asian countries has not been reported. METHODS: This retrospective study summarizes the changes in practice and outcome during the period 2005 to 2015 from a tertiary referral center in Hong Kong. Patients were divided into 3 groups according to the NAC they received: chemotherapy only (CH), chemotherapy plus trastuzumab (CH-H), and chemotherapy plus double anti- HER2 therapies (CH-DH). RESULTS: There were 177 patients captured during this period and significantly more pre-menopausal women in the groups receiving anti-HER2 therapies (*p < 0.01). Rate of pCR was higher in patients who received anti-HER2 therapies (*p < 0.01), with patients in CH-DH group had more pCR than those in CH-H group (**p < 0.01). This was accompanied by a trend in increase rate of breast conservation therapy (BCT). The estimated recurrent-free-survival (censored) at 5 years was 57% (CH), 76% (CH-H), and 93% (CH-DH) respectively with a mean follow up of 4.2 years. Longer follow up would be required for conclusive results. CONCLUSIONS: Current approach of NAC using CH-H and CH-DH appeared to derive similar favourable pCR rate in Asian patients compared with published results. The option of BCT after the enhanced tumor shrinkage achieved with NAC may explain the preference of NAC in HER-positive premenopausal women. Combination NAC with double anti-HER2 therapy is likely to become the preferred option to achieve higher BCT rates.
DescriptionPoster Presentation 2 - Breast Cancer: no. 71P
This journal suppl. entitled: ESMO Asia Congress, 18-21 December 2015, Singapore
Persistent Identifierhttp://hdl.handle.net/10722/235031
ISSN
2015 Impact Factor: 9.269
2015 SCImago Journal Rankings: 4.362

 

DC FieldValueLanguage
dc.contributor.authorChiu, WYJ-
dc.contributor.authorLeung, RCY-
dc.contributor.authorTang, YFV-
dc.contributor.authorCheuk, I-
dc.contributor.authorLo, J-
dc.contributor.authorWong, HYH-
dc.contributor.authorKwok, G-
dc.contributor.authorSuen, TKD-
dc.contributor.authorYau, TCC-
dc.contributor.authorKwong, A-
dc.date.accessioned2016-10-14T13:50:49Z-
dc.date.available2016-10-14T13:50:49Z-
dc.date.issued2015-
dc.identifier.citationThe 2015 Congress of the European Society for Medical Oncology Asia (ESMO Asia 2015), Singapore, 18-22 December 2015. In Annals of Oncology, 2015, v. 26 suppl. 9, p. ix22, abstract no. 71P-
dc.identifier.issn0923-7534-
dc.identifier.urihttp://hdl.handle.net/10722/235031-
dc.descriptionPoster Presentation 2 - Breast Cancer: no. 71P-
dc.descriptionThis journal suppl. entitled: ESMO Asia Congress, 18-21 December 2015, Singapore-
dc.description.abstractAIM/BACKGROUND: Over the last 10 years we witnessed major changes in treatment for locally advanced HER2-positive breast cancer. The emergence of multiple anti-HER2 therapies and recognition of pathological complete response (pCR) as the surrogate marker for survival are the major landmarks. The clinical benefit of this approach and effects on patient behaviour in Asian countries has not been reported. METHODS: This retrospective study summarizes the changes in practice and outcome during the period 2005 to 2015 from a tertiary referral center in Hong Kong. Patients were divided into 3 groups according to the NAC they received: chemotherapy only (CH), chemotherapy plus trastuzumab (CH-H), and chemotherapy plus double anti- HER2 therapies (CH-DH). RESULTS: There were 177 patients captured during this period and significantly more pre-menopausal women in the groups receiving anti-HER2 therapies (*p < 0.01). Rate of pCR was higher in patients who received anti-HER2 therapies (*p < 0.01), with patients in CH-DH group had more pCR than those in CH-H group (**p < 0.01). This was accompanied by a trend in increase rate of breast conservation therapy (BCT). The estimated recurrent-free-survival (censored) at 5 years was 57% (CH), 76% (CH-H), and 93% (CH-DH) respectively with a mean follow up of 4.2 years. Longer follow up would be required for conclusive results. CONCLUSIONS: Current approach of NAC using CH-H and CH-DH appeared to derive similar favourable pCR rate in Asian patients compared with published results. The option of BCT after the enhanced tumor shrinkage achieved with NAC may explain the preference of NAC in HER-positive premenopausal women. Combination NAC with double anti-HER2 therapy is likely to become the preferred option to achieve higher BCT rates.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/-
dc.relation.ispartofAnnals of Oncology-
dc.rightsPre-print: Journal Title] ©: [year] [owner as specified on the article] Published by Oxford University Press [on behalf of xxxxxx]. All rights reserved. Pre-print (Once an article is published, preprint notice should be amended to): This is an electronic version of an article published in [include the complete citation information for the final version of the Article as published in the print edition of the Journal.] Post-print: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxxxxx [insert URL that the author will receive upon publication here].-
dc.titleEvolution of neoadjuvant chemotherapy in locally advanced HER2-positive breast cancer over 10 years in Hong Kong-
dc.typeConference_Paper-
dc.identifier.emailChiu, WYJ: jwychiu@hku.hk-
dc.identifier.emailLeung, RCY: cyleungr@hkucc.hku.hk-
dc.identifier.emailTang, YFV: vyftang@hku.hk-
dc.identifier.emailWong, HYH: hildahy@hku.hk-
dc.identifier.emailSuen, TKD: suentkd@hku.hk-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.emailKwong, A: avakwong@hku.hk-
dc.identifier.authorityChiu, WYJ=rp01917-
dc.identifier.authorityYau, TCC=rp01466-
dc.identifier.authorityKwong, A=rp01734-
dc.identifier.doi10.1093/annonc/mdv519.20-
dc.identifier.hkuros267916-
dc.identifier.volume26-
dc.identifier.issuesuppl. 9-
dc.identifier.spageix22, abstract no. 71P-
dc.identifier.epageix22, abstract no. 71P-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats